Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 187 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Myositis Clear all
Completed Not applicable Interventional

Fitness Integrative Training for Pediatric Rheumatology Disorders

NCT06556992
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis
Interventions
FIT Teens
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study and Treatment of Inflammatory Muscle Diseases

NCT00001265
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
16 Years and older
Enrollment
1,325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

NCT03312634
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
4 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Arimoclomol in Inclusion Body Myositis (IBM)

NCT02753530
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol, Placebo
Drug · Other
Lead sponsor
ZevraDenmark
Industry
Eligibility
45 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting No phase listed Observational

The Fibrodysplasia Ossificans Progressiva (FOP) Registry

NCT02745158
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Not listed
Lead sponsor
The International FOP Association
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2040
U.S. locations
1
States / cities
North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Muscle Health Measurements Using Electrical Impedance Myography

NCT07502989
View directory record Official record
Conditions
Myopathy, Muscular Dystrophies, Myositis, Myofibrillar Myopathy, Congenital Myopathy, Distal Myopathy, Myopathies
Interventions
Electrical Impedance Myography
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

NCT05039515
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
IPN60130, Placebo
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
5 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

Descartes-08 in Autoantibody Myositis

NCT07391605
View directory record Official record
Conditions
Antisynthetase Syndrome
Interventions
Descartes-08, Placebo
Drug · Other
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Orange, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

NCT00001261
View directory record Official record
Conditions
Dermatomyositis, Inclusion Body Myositis, Polymyositis
Interventions
Gamma Globulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

Urine Sample Collection From FOP Patients

NCT02066324
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
5 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020
View directory record Official record
Conditions
Dermatomyositis
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104
View directory record Official record
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide, Fludarabine
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
16
States / cities
Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

NCT03529955
View directory record Official record
Conditions
Dermatomyositis, Adult Type
Interventions
Apremilast 30mg
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Etanercept in Dermatomyositis

NCT00112385
View directory record Official record
Conditions
Dermatomyositis
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

NCT02573467
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
Bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

NCT03813160
View directory record Official record
Conditions
Dermatomyositis
Interventions
Lenabasum 20 mg, Lenabasum 5 mg, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

NCT00979654
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Sifalimumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

Lithium in Inclusion Body Myositis (IBM)

NCT00917956
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Not listed
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
30 Years to 88 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02322255
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Early Phase 1 Interventional

Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study

NCT02271165
View directory record Official record
Conditions
Dermatomyositis
Interventions
Immunoglobulin (Hizentra)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 21, 2026, 2:42 AM EDT